EXEL · Exelixis
50 filings
EXEL 10-Q Quarterly Reports
Exelixis - 50 quarterly reports
EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 16, 2016
- 10-K · Feb 29, 2016
- 8-K · Feb 29, 2016
- 10-Q · May 4, 2016
- 8-K · May 4, 2016
- 8-K · May 26, 2016
- 10-Q · Aug 3, 2016
- 8-K · Aug 3, 2016
- 8-K · Aug 9, 2016
- 8-K · Aug 22, 2016
- 8-K · Sep 26, 2016
- 10-Q/A · Sep 30, 2016
- 8-K · Nov 3, 2016
- 10-Q · Nov 3, 2016
- 8-K · Nov 22, 2016
- 8-K · Dec 21, 2016
- 8-K · Jan 31, 2017
- 8-K · Feb 27, 2017
- 10-K · Feb 27, 2017
- 10-Q · May 1, 2017
- 8-K · May 1, 2017
- 8-K · May 2, 2017
- 8-K · May 11, 2017
- 8-K · May 25, 2017
- 10-Q/A · Jul 14, 2017
- 8-K · Jul 20, 2017
- 8-K · Aug 2, 2017
- 10-Q · Aug 2, 2017
- 8-K/A · Sep 8, 2017
- 8-K · Sep 8, 2017
- 8-K · Nov 1, 2017
- 10-Q · Nov 1, 2017
- 8-K · Feb 16, 2018
- 10-K · Feb 26, 2018
- 8-K · Feb 26, 2018
- 8-K · Apr 9, 2018
- 8-K · May 2, 2018
- 10-Q · May 2, 2018
- 8-K · May 24, 2018
- 10-Q · Aug 1, 2018
- 8-K · Aug 1, 2018
- 10-Q · Nov 1, 2018
- 8-K · Nov 1, 2018
- 8-K · Feb 12, 2019
- 8-K · Feb 21, 2019
- 10-K · Feb 22, 2019
- 8-K · Mar 5, 2019
- 8-K · Apr 5, 2019
- 8-K · Apr 25, 2019
- 8-K · May 1, 2019
- 10-Q · May 1, 2019
- 8-K · May 23, 2019
- 8-K · Jun 20, 2019
- 10-Q · Jul 31, 2019
- 8-K · Jul 31, 2019
- 8-K · Sep 26, 2019
- 8-K · Oct 7, 2019
- 10-Q · Oct 30, 2019
- 8-K · Oct 30, 2019
- 8-K · Dec 19, 2019
- 8-K · Jan 13, 2020
- 8-K · Feb 20, 2020
- 10-K · Feb 25, 2020
- 8-K · Feb 25, 2020
- 8-K · Mar 2, 2020
- 8-K · Apr 20, 2020
- 8-K · May 5, 2020
- 10-Q · May 5, 2020
- 8-K · May 12, 2020
- 8-K · May 22, 2020
- 8-K · Aug 6, 2020
- 10-Q · Aug 6, 2020
- 8-K · Nov 5, 2020
- 10-Q · Nov 5, 2020
- 8-K · Jan 11, 2021
- 8-K · Feb 5, 2021
- 8-K · Feb 10, 2021
- 10-K · Feb 11, 2021
- 8-K · Mar 3, 2021
- 8-K · Mar 5, 2021
- 10-Q · May 6, 2021
- 8-K · May 6, 2021
- 8-K · May 11, 2021
- 8-K · May 27, 2021
- 8-K · Jun 21, 2021
- 8-K · Jun 21, 2021
- 8-K · Aug 5, 2021
- 10-Q · Aug 5, 2021
- 8-K · Nov 2, 2021
- 10-Q · Nov 2, 2021
- 8-K · Dec 17, 2021
- 8-K · Jan 10, 2022
- 8-K · Feb 17, 2022
- 10-K · Feb 18, 2022
- 8-K · Feb 23, 2022
- 8-K · Apr 13, 2022
- 10-Q · May 10, 2022
- 8-K · May 10, 2022
- 8-K · May 27, 2022
- 8-K · Jul 19, 2022
- 8-K · Aug 9, 2022
- 10-Q · Aug 9, 2022
- 8-K · Sep 2, 2022
- 10-Q · Nov 1, 2022
- 8-K · Nov 1, 2022
- 8-K · Dec 15, 2022
- 8-K · Jan 9, 2023
- 10-K · Feb 7, 2023
- 8-K · Feb 7, 2023
- 8-K · Mar 20, 2023
- 8-K · Mar 22, 2023
- 8-K · Apr 13, 2023
- 8-K · May 8, 2023
- 10-Q · May 9, 2023
- 8-K · May 9, 2023
- 8-K · Jun 5, 2023
- 8-K · Jul 24, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 1, 2023
- 8-K · Aug 23, 2023
- 8-K · Sep 19, 2023
- 10-Q · Nov 1, 2023
- 8-K · Nov 1, 2023
- 8-K · Dec 20, 2023
- 8-K · Jan 8, 2024
- 10-K · Feb 6, 2024
- 8-K · Feb 6, 2024
- 8-K · Mar 29, 2024
- 8-K · Apr 30, 2024
- 10-Q · Apr 30, 2024
- 8-K · May 10, 2024
- 8-K · May 20, 2024
- 8-K · Jun 3, 2024
- 8-K · Aug 6, 2024
- 10-Q · Aug 6, 2024
- 8-K · Oct 15, 2024
- 8-K · Oct 15, 2024
- 10-Q · Oct 29, 2024
- 8-K · Oct 29, 2024
- 8-K · Jan 13, 2025
- 8-K · Feb 11, 2025
- 10-K · Feb 11, 2025
- 8-K · Feb 21, 2025
- 8-K · Mar 31, 2025
- 10-Q · May 13, 2025
- 8-K · May 13, 2025
- 8-K · Jun 2, 2025
- 8-K · Jul 28, 2025
- 10-Q · Jul 28, 2025
- 8-K · Aug 29, 2025
- 10-Q · Nov 4, 2025
- 8-K · Nov 4, 2025
- 8-K · Nov 7, 2025
- 8-K · Jan 12, 2026
- 8-K · Feb 10, 2026
- 10-K · Feb 10, 2026
- 10-Q · May 5, 2026
- 8-K · May 5, 2026
- 8-K · May 29, 2026
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026
- 8-K · Aug 31, 2026
- 8-K · Sep 11, 2026
- 8-K · Oct 29, 2026
- 10-Q · Oct 29, 2026
- 2027-Q3Oct 29, 2026
Exelixis Quarterly Report for Q3 Ended Oct 2, 2026
Exelixis, Inc. reported net product revenues of $604.9 million for the third quarter of 2026, up from $542.9 million a year earlier, and total revenues of $658.7 million versus $597.8 million. Net income was $218.1 million, or $0.85 per diluted share, compared with $193.6 million, or $0.69 per diluted share, in the prior-year quarter. Growth was driven mainly by CABOMETYX, with the company citing a 6% increase in units sold and a 5% increase in average net selling price, while research and development ($209.5 million) and selling, general and administrative ($154.6 million) expenses rose as the company prepared for zanzalintinib's anticipated launch. The company ended the period with $1.4 billion in cash, cash equivalents and marketable securities, down from $1.7 billion at December 31, 2025, largely due to $1.0 billion of share repurchases in the first nine months. Operating cash flow was $839.5 million for the nine months, and management states it expects current resources to fund operations for at least 12 months. Under the May 2026 repurchase program, $347.9 million remained available as of September 30, 2026. Key pipeline and legal developments include the FDA extending the review of the zanzalintinib NDA (with atezolizumab for metastatic colorectal cancer) to a PDUFA date of March 3, 2027, and the Federal Circuit affirming the validity of several CABOMETYX patents against MSN, with a separate trial scheduled for November 2026. The FDA also granted full approval to Handa's 505(b)(2) NDA for a cabozantinib product on September 3, 2026, and the company entered a settlement and license agreement with Azurity on October 28, 2026.
- 2027-Q2Aug 5, 2026
Exelixis Quarterly Report for Q2 Ended Jul 3, 2026
Exelixis, Inc. reported strong second-quarter 2026 results, with total revenues of $628.7 million, up from $568.3 million in the second quarter of 2025, and net income of $212.1 million, or $0.82 per diluted share, compared with $184.8 million, or $0.65 per diluted share, a year earlier. Net product revenues were $573.0 million, driven by CABOMETYX, which generated $570.6 million in the quarter. Research and development expenses were $212.0 million and selling, general and administrative expenses were $147.6 million, with SG&A rising in part on pre-launch marketing for zanzalintinib. Cash, cash equivalents and marketable securities totaled $1.38 billion at June 30, 2026, down from $1.66 billion at December 31, 2025, as the company returned capital through stock repurchases. Repurchases under the two stock repurchase programs totaled $902.2 million through June 30, 2026, with about $597.8 million remaining under the May 2026 program. Management states that current cash and cash equivalents and marketable securities, together with product and collaboration revenues, will fund operations for at least 12 months. The filing highlights ongoing pipeline and regulatory events. Zanzalintinib, in combination with atezolizumab, is under FDA review for previously treated metastatic colorectal cancer with a PDUFA target action date of December 3, 2026. The STELLAR-303 final overall survival analysis in the non-liver metastases subpopulation was not statistically significant. The company also disclosed multiple Paragraph IV patent challenges to CABOMETYX from generic and 505(b)(2) filers, and the filing notes that the sale of competing cabozantinib products before patent expiration could materially harm the business.
- 2027-Q1May 5, 2026
Exelixis Quarterly Report for Q1 Ended Apr 3, 2026
Exelixis, Inc. reported first-quarter 2026 total revenues of $610.8 million, up from $555.4 million in the first quarter of 2025, with net product revenues of $555.0 million versus $513.3 million a year earlier. Net income rose to $210.5 million, or $0.79 per diluted share, compared with $159.6 million, or $0.55 per diluted share, in the prior-year quarter. Growth was driven mainly by CABOMETYX, which generated $552.8 million in net product revenues, and by collaboration revenues of $55.8 million, which included a $7.7 million recognition tied to an $8.0 million Takeda commercial milestone. Research and development expenses declined to $199.9 million from $212.2 million, reflecting lower clinical trial costs, while selling, general and administrative expenses rose to $139.6 million, citing marketing for the anticipated zanzalintinib launch. Capital deployment was significant. Cash, cash equivalents and marketable securities fell to $1.43 billion from $1.66 billion at December 31, 2025, primarily because of $430.4 million in cash paid for share repurchases. The company had repurchased 13.7 million shares for $590.6 million under its October 2025 program, with about $159.4 million remaining, and in May 2026 its Board authorized an additional $750.0 million repurchase program through December 31, 2027. Working capital declined to $837.7 million. Management stated that existing resources should support operations for at least 12 months. The filing highlights pipeline and regulatory events, including FDA acceptance of the zanzalintinib NDA for previously treated metastatic colorectal cancer with a PDUFA target date of December 3, 2026, and the expected final OS analysis of STELLAR-303 in mid-2026. It also discusses generic litigation: MSN, Sun (settled in December 2025), and Azurity are consolidated for trial scheduled November 2, 2026, and a Handa 505(b)(2) application for cabozantinib capsules is under challenge.
- 2026-Q3Nov 4, 2025
Exelixis Quarterly Report for Q3 Ended Oct 3, 2025
Exelixis, Inc. reported third-quarter 2025 total revenues of $597.8 million, up from $539.5 million a year earlier, driven by net product revenues of $542.9 million, which rose from $478.1 million. Net product revenues were primarily CABOMETYX, at $539.9 million for the quarter. Collaboration revenues declined to $54.8 million from $61.5 million, as license revenues fell with fewer milestones. Income from operations was $236.5 million, versus $136.1 million a year earlier, and net income was $193.6 million, or $0.69 per diluted share, compared with $118.0 million, or $0.40 per diluted share. The quarter included $19.8 million in restructuring expenses tied to the 2025 Plan, which closed the King of Prussia, Pennsylvania office. For the nine months ended September 30, 2025, net cash from operating activities was $550.8 million. Cash, cash equivalents and marketable securities totaled $1.6 billion, down from $1.7 billion at December 31, 2024, mainly because of $689.9 million in share repurchase payments. As of September 30, 2025, $104.7 million remained under existing repurchase authorizations, and in October 2025 the board authorized an additional $750.0 million through December 31, 2026. Management states that current resources should fund operations for at least 12 months. The filing highlights pending generic challenges to CABOMETYX, including ANDA litigation with MSN, Sun, and Azurity, with trial scheduled for November 2, 2026. Exelixis settled with Biocon, which will be licensed to market a generic version in the U.S. beginning January 1, 2031. The company also reported positive top-line results from the STELLAR-303 phase 3 trial of zanzalintinib, and it intends to file a New Drug Application by the end of 2025, subject to the availability of government services.
- 2026-Q2Jul 28, 2025
Exelixis Quarterly Report for Q2 Ended Jul 4, 2025
Exelixis, Inc. reported second-quarter 2025 total revenues of $568.3 million, down from $637.2 million in the second quarter of 2024, while net product revenues rose to $520.0 million from $437.6 million. Net income for the quarter was $184.8 million, or $0.65 per share on a diluted basis, compared with $226.1 million, or $0.77 per share diluted, a year earlier. For the six months ended June 30, 2025, total revenues were $1.12 billion and net income was $344.5 million. Growth in CABOMETYX net product revenues was driven by continued demand for the nivolumab combination in first-line advanced renal cell carcinoma, and the company projects net product revenues may increase for the remainder of 2025 following the first-quarter 2025 FDA approval for previously treated advanced neuroendocrine tumors. Collaboration revenues fell to $48.2 million in the quarter from $199.6 million, reflecting the $150.0 million Ipsen commercial milestone recognized in the prior-year period. Cash, cash equivalents and marketable securities totaled $1.39 billion at June 30, 2025, down from $1.75 billion at December 31, 2024, primarily due to share repurchases. The company repurchased $796.3 million of common stock under two $500.0 million authorizations, leaving approximately $203.7 million available through December 31, 2025. Management states that current cash and marketable securities, together with net product and collaboration revenues, will enable it to maintain operations for at least 12 months. Research and development expenses were $200.4 million in the quarter, and the company expects clinical trial costs to increase for the remainder of 2025, driven mainly by zanzalintinib studies. The filing also discusses significant patent litigation over CABOMETYX generics. In July 2025, Exelixis entered into a settlement and license agreement with Biocon that grants a U.S. generic license beginning January 1, 2031, subject to FDA approval. Litigation with MSN, Sun and Azurity remains ongoing, and the company states it is not possible at this time to determine the likelihood of an unfavorable outcome. The company also reported positive top-line results from the STELLAR-303 phase 3 trial of zanzalintinib in June 2025 and intends to discuss a New Drug Application filing with U.S. regulators.
- 2026-Q1May 13, 2025
Exelixis Quarterly Report for Q1 Ended Apr 4, 2025
Exelixis, Inc. reported first-quarter 2025 total revenues of $555.4 million, up from $425.2 million a year earlier, driven by net product revenues of $513.3 million compared with $378.5 million. CABOMETYX net product revenues were $510.9 million, and the filing attributes the increase primarily to a 25% increase in CABOMETYX units sold and a 9% increase in average net selling price. Net income was $159.6 million, or $0.55 per diluted share, versus $37.3 million, or $0.12 per share, in the prior-year quarter. The prior-year period included $32.8 million in restructuring expenses, which were absent in 2025. Research and development expenses declined to $212.2 million from $227.7 million, while selling, general and administrative expenses rose to $137.2 million from $114.0 million. Cash flow from operations was $211.4 million, compared with $68.8 million a year earlier. The company ended the quarter with $1.65 billion in cash, cash equivalents and marketable securities, down from $1.75 billion at year-end 2024, after repurchasing $283.9 million of common stock in cash during the quarter. Under two authorizations totaling $1.0 billion, $494.5 million of stock has been repurchased to date, leaving about $505.5 million available through December 31, 2025. The company states it expects its current resources to fund operations for at least 12 months. The filing highlights ongoing patent litigation over CABOMETYX. Multiple generic ANDA filers (MSN, Sun, Biocon) and Azurity's 505(b)(2) application have filed Paragraph IV certifications, and the company has sued each of them. In the MSN II case, the Delaware District Court ruled in October 2024 that the effective date of any FDA approval of MSN's ANDA would not be earlier than January 15, 2030, and MSN has appealed. The company also reported an FDA approval in March 2025 for CABOMETYX in previously treated advanced neuroendocrine tumors, and it stated that it expects net product revenues to increase for the remainder of 2025 partly because of that approval.
- 2025-Q3Oct 29, 2024
Exelixis Quarterly Report for Q3 Ended Sep 27, 2024
Exelixis, Inc. reported third-quarter 2024 total revenues of $539.5 million, up from $471.9 million in the third quarter of 2023, with net income of $118.0 million, or $0.40 per diluted share, compared with net income of $1.0 million in the prior-year quarter. Net product revenues were $478.1 million, driven by CABOMETYX, which generated $475.7 million in the quarter. For the nine months ended September 30, 2024, total revenues were $1.60 billion and net income was $381.4 million, aided by $299.9 million in license revenues, including a $150.0 million commercial milestone from Ipsen. Operating results also included a $51.7 million non-cash impairment charge related to Alameda leased facilities and $33.4 million in restructuring expenses under the 2024 Restructuring Plan. The company ended the quarter with $1.7 billion in cash, cash equivalents and marketable securities, unchanged in total from December 31, 2023, after repurchasing $461.6 million of common stock in the nine-month period. Management states that current resources should fund operations for at least 12 months. A new $500 million share repurchase authorization was approved in August 2024, with approximately $487.6 million remaining as of September 30, 2024. Investors should note the ongoing generic competition risk to CABOMETYX. The company has settled litigation with Teva and Cipla with licenses beginning January 1, 2031, and a Delaware court ruled in October 2024 that generic entry under MSN's ANDA cannot occur before January 15, 2030. Sun Pharmaceutical Industries also filed a Paragraph IV notice in September 2024, which the company is evaluating. Pipeline activity includes the sNDA for cabozantinib in pNET/epNET with a PDUFA target action date of April 3, 2025, and the phase 3 STELLAR-303 trial for zanzalintinib, with preliminary results expected in 2025.
- 2025-Q2Aug 6, 2024
Exelixis Quarterly Report for Q2 Ended Jun 28, 2024
Exelixis, Inc. reported a strong second quarter of 2024, with total revenues of $637.2 million for the three months ended June 30, 2024, up from $469.8 million a year earlier, and net income of $226.1 million, or $0.77 per diluted share, compared with $81.2 million, or $0.25 per diluted share, in the prior-year quarter. The result was driven largely by license revenues of $195.0 million, which include a $150.0 million commercial milestone from Ipsen tied to $600.0 million in cumulative cabozantinib net sales over four consecutive quarters. Net product revenues rose to $437.6 million from $409.6 million, with CABOMETYX sales increasing on higher unit volume following the approval of CABOMETYX in combination with nivolumab for first-line advanced RCC. For the six months ended June 30, 2024, total revenues were $1.06 billion and net income was $263.4 million. Results for the period also reflect $33.3 million in restructuring expenses under the 2024 Restructuring Plan, which was substantially completed by the end of the second quarter. Cash, cash equivalents and investments totaled $1.4 billion at June 30, 2024, down from $1.7 billion at December 31, 2023, reflecting $450.0 million of share repurchases completed under the program authorized in January 2024. In August 2024, the Board authorized a new repurchase program of up to $500.0 million through the end of 2025. The filing also highlights ongoing legal and pipeline developments. Settlements with Cipla and earlier with Teva provide U.S. generic entry for CABOMETYX no earlier than January 1, 2031, while the MSN II litigation remains pending with a judgment expected in the second half of 2024. On the pipeline side, the company reported an FDA-accepted sNDA for cabozantinib in pNET and epNET with a PDUFA date of April 3, 2025, and is discontinuing XB002 and prioritizing zanzalintinib, XL309 and XB010.
- 2025-Q1Apr 30, 2024
Exelixis Quarterly Report for Q1 Ended Mar 29, 2024
Exelixis, Inc. reported total revenues of $425.2 million for the first quarter of 2024, up from $408.8 million in the prior-year quarter, with net product revenues of $378.5 million, up from $363.4 million. CABOMETYX accounted for $376.4 million of net product revenues. Net income was $37.3 million, or $0.12 per share basic and diluted, compared with $40.0 million, or $0.12 per share, a year earlier. The quarter included $32.8 million of restructuring expenses tied to the 2024 Restructuring Plan, which is intended to reduce the workforce and rebalance the cost structure. Research and development expenses fell to $227.7 million from $234.2 million, and selling, general and administrative expenses fell to $114.0 million from $131.4 million. Cash, cash equivalents and investments totaled $1.6 billion at March 31, 2024, compared with $1.7 billion at December 31, 2023. Net cash provided by operating activities was $68.8 million, down from $84.4 million, and the company paid $185.4 million to repurchase common stock. Under a stock repurchase program authorized in January 2024 for up to $450 million before the end of 2024, the company repurchased 8.6 million shares for an aggregate $190.7 million, leaving approximately $259.3 million available. Total stockholders' equity declined to $2.13 billion from $2.26 billion, and the accumulated deficit increased to $258.9 million. The filing highlights ongoing patent litigation over CABOMETYX. A bench trial in the MSN II case occurred in October 2023, with a judgment expected during the first half of 2024. On March 27, 2024, Cipla amended its ANDA to add further Paragraph IV certifications, which the company is evaluating. The filing states that any generic CABOMETYX approved and launched before patent expiration could significantly decrease U.S. revenues. The company also disclosed a settlement with Teva that grants Teva a license to market a generic CABOMETYX in the U.S. beginning January 1, 2031, if approved by the FDA.
- 2024-Q3Nov 1, 2023
Exelixis Quarterly Report for Q3 Ended Sep 29, 2023
Exelixis, Inc. reported third-quarter 2023 total revenues of $471.9 million, up from $411.7 million a year earlier, driven by net product revenues of $426.5 million (CABOMETYX $422.2 million). However, research and development expenses rose to $332.6 million from $198.8 million, largely due to an $80.0 million upfront payment to Insilico for the XL309 license and higher personnel and clinical trial costs. As a result, the company recorded income from operations of $(17.6) million, compared with $82.6 million a year earlier, and net income of $1.0 million, or $0.00 per diluted share, versus $73.2 million, or $0.23 per share, in the prior-year quarter. Interest income rose to $23.1 million from $9.5 million, reflecting higher interest rates. As of September 30, 2023, Exelixis held $1.9 billion in cash, cash equivalents and investments, compared with $2.1 billion at December 31, 2022, and management stated it expects current resources and revenues to fund operations for at least 12 months. During the first nine months of 2023 the company repurchased $344.8 million of common stock under a program authorized in March 2023 for up to $550 million, with approximately $205.2 million remaining available for repurchases before year-end 2023. Net cash provided by operating activities for the nine months was $322.8 million. The filing also highlights ongoing litigation over generic CABOMETYX. A settlement with Teva grants Teva a license to market a generic version in the U.S. beginning January 1, 2031, if approved by the FDA. The MSN II case is awaiting a judgment expected in the first half of 2024 following an October 2023 bench trial, and a Cipla ANDA case has been administratively closed. Pipeline updates include positive top-line results from the phase 3 CONTACT-02 trial in mCRPC, which met one of two primary endpoints, and a phase 3 COSMIC-313 interim overall survival analysis that did not reach statistical significance, with the trial continuing to its next analysis in 2024.
- 2024-Q2Aug 1, 2023
Exelixis Quarterly Report for Q2 Ended Jun 30, 2023
Exelixis, Inc. reported financial results for the quarter ended June 30, 2023 in this Form 10-Q. Total revenues for the second quarter were $469.8 million, up from $419.4 million a year earlier, driven by net product revenues of $409.6 million (CABOMETYX $403.3 million). Income from operations was $77.8 million, and net income was $81.2 million, or $0.25 per share basic and diluted, compared with $70.7 million, or $0.22 per share, in the second quarter of 2022. Research and development expenses rose to $232.6 million and selling, general and administrative expenses rose to $141.7 million. For the six months ended June 30, 2023, total revenues were $878.6 million and net income was $121.2 million. The company ended the quarter with $2.1 billion in cash, cash equivalents and investments, and states it expects its resources to fund operations for at least 12 months. During the six months, Exelixis repurchased $127.0 million of common stock under a $550 million program authorized in March 2023, leaving approximately $423.0 million available. Operating cash flow for the six months was $205.4 million. The filing highlights legal and competitive risk around CABOMETYX. On July 18, 2023, the company entered into a settlement and license agreement with Teva that grants Teva a license to market a generic version in the U.S. beginning January 1, 2031, if approved by the FDA. Litigation against MSN and Cipla over generic ANDA filings remains ongoing, and the filing states that a generic launch could significantly decrease U.S. CABOMETYX revenues. The filing also notes that the Inflation Reduction Act and other drug pricing initiatives could affect future revenues.
- 2024-Q1May 9, 2023
Exelixis Quarterly Report for Q1 Ended Mar 31, 2023
Exelixis, Inc. reported first-quarter 2023 net product revenues of $363.4 million, up from $310.3 million a year earlier, and total revenues of $408.8 million versus $356.0 million. CABOMETYX net product revenues were $361.8 million, and the filing attributes the increase primarily to a 10% rise in CABOMETYX units sold, related to the FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment for advanced RCC, plus an 8% increase in average net selling price. Net income was $40.0 million, or $0.12 per diluted share, compared with $68.6 million, or $0.21 per share, in the prior-year quarter. Research and development expenses rose to $234.2 million from $156.7 million, driven mainly by a $35.0 million development milestone paid to Sairopa B.V. upon the effective date of the initial new drug application for ADU-1805, along with higher personnel and other development costs. The balance sheet remained strong, with $2.1 billion in cash, cash equivalents, restricted cash equivalents and investments as of March 31, 2023. The company stated that its current cash, short-term investments, net product revenues and collaboration revenues should fund operations for at least 12 months and thereafter for the foreseeable future. In March 2023, the Board authorized a share repurchase program of up to $550 million of common stock before the end of 2023, though no shares were repurchased during the quarter. The filing highlights ongoing legal and competitive risk to CABOMETYX. Generic ANDA filers MSN, Teva and Cipla have challenged its patents. The Delaware District Court ruled in January 2023 against MSN's invalidity challenge in MSN I, with judgment that generic approval cannot take effect before August 14, 2026. The MSN II bench trial is scheduled for October 2023, and the Cipla case has been administratively stayed. The company stated it cannot determine the likelihood or amount of loss from an unfavorable outcome.
- 2023-Q3Nov 1, 2022
Exelixis Quarterly Report for Q3 Ended Sep 30, 2022
Exelixis, Inc. reported strong third-quarter 2022 results in this Form 10-Q for the period ended September 30, 2022. Total revenues were $411.7 million for the quarter, up from $328.4 million a year earlier, driven by net product revenues of $366.5 million, which reflect CABOMETYX sales. Net income was $73.2 million, or $0.23 per share basic and diluted, compared with $38.2 million, or $0.12 per share, in the prior-year quarter. For the nine months, net income was $212.5 million, or $0.65 per share diluted, and net cash provided by operating activities was $288.9 million. The company ended the quarter with $2.1 billion in cash, cash equivalents, restricted cash equivalents and investments, up from $1.9 billion at December 31, 2021, and management states this is sufficient to fund operations for at least 12 months. Research and development expenses rose to $198.8 million in the quarter from $163.4 million, and management projects R&D and selling, general and administrative expenses may increase for the remainder of 2022. The filing also describes new business development deals in November 2022, including a $60.0 million upfront fee for a warrant tied to Cybrexa's CBX-12 and a $40.0 million upfront option payment to Sairopa for ADU-1805. The filing highlights material litigation risk: MSN and Teva have filed ANDAs seeking approval of generic CABOMETYX, and the company states that generic entry could significantly decrease U.S. CABOMETYX revenues. A bench trial in the MSN I case occurred in May 2022 with a judgment expected in the fourth quarter of 2022, and the company says it cannot determine the likelihood or amount of any unfavorable outcome.
- 2023-Q2Aug 9, 2022
Exelixis Quarterly Report for Q2 Ended Jul 1, 2022
Exelixis, Inc. reported strong second-quarter 2022 results in this Form 10-Q. Total revenues for the three months ended June 30, 2022 were $419.4 million, up from $385.2 million a year earlier, driven by net product revenues of $347.0 million (CABOMETYX $339.2 million) and license revenues of $57.5 million. Net income was $70.7 million, or $0.22 per share basic and diluted, compared with $96.1 million, or $0.30 per diluted share, in the prior-year quarter. For the six months ended June 30, 2022, net income was $139.2 million on total revenues of $775.4 million. Research and development expenses rose to $199.5 million for the quarter from $148.8 million, and selling, general and administrative expenses rose to $122.8 million from $98.5 million, reflecting continued investment in pipeline and commercial activities. The balance sheet remained strong, with cash, cash equivalents, restricted cash equivalents and investments totaling $2.0 billion at June 30, 2022, and stockholders' equity of $2.39 billion. Net cash provided by operating activities for the six months was $178.8 million. Management said it expects cash and investments plus operating cash flows to fund operations for at least 12 months from the filing date. The principal risk highlighted is patent litigation over CABOMETYX. MSN Pharmaceuticals and Teva have filed abbreviated new drug applications seeking approval of generic versions, and Exelixis has filed multiple lawsuits against them. A bench trial on earlier patents occurred in May 2022, with a judgment expected in the third or fourth quarter of 2022. The company stated that any earlier generic launch could significantly decrease U.S. CABOMETYX revenues.
- 2023-Q1May 10, 2022
Exelixis Quarterly Report for Q1 Ended Apr 1, 2022
Exelixis, Inc. reported first-quarter 2022 results in this Form 10-Q, with total revenues of $355.98 million, up from $270.23 million in the prior-year quarter, and net income of $68.57 million, or $0.21 per diluted share, compared with net income of $1.60 million in the first quarter of 2021. Net product revenues were $310.30 million, driven by CABOMETYX ($302.81 million) and COMETRIQ ($7.49 million). The filing attributes the net product revenue increase primarily to a 33% increase in units sold following the FDA's January 2021 approval of CABOMETYX in combination with OPDIVO for first-line advanced RCC. Research and development expenses were $156.67 million and selling, general and administrative expenses were $102.86 million, leaving income from operations of $83.24 million. The balance sheet remained strong, with cash, cash equivalents, restricted cash equivalents and investments of $1.99 billion at March 31, 2022, compared with $1.85 billion at December 31, 2021, and total stockholders' equity of $2.29 billion. Operating cash flow was $147.72 million, which included collection of a $100.0 million milestone payment from Ipsen. The company stated it expects its current cash and cash equivalents, short-term investments, product revenues and collaboration revenues to fund operations for at least 12 months following the filing date. The most significant risk flagged is patent litigation over generic CABOMETYX. A three-day bench trial against MSN Pharmaceuticals is scheduled to begin May 16, 2022, and the filing states that a generic version of CABOMETYX could significantly decrease U.S. CABOMETYX revenues. The company also reported that the COSMIC-312 final overall survival analysis showed neither improvement nor detriment, so it does not intend to submit a supplemental New Drug Application for that HCC combination.
- 2022-Q3Nov 2, 2021
Exelixis Quarterly Report for Q3 Ended Oct 1, 2021
Exelixis, Inc. reported a strong third quarter of 2021, with total revenues of $328.4 million, up from $231.1 million in the third quarter of 2020, and net income of $38.2 million, or $0.12 per diluted share, compared with a net loss of $32.0 million a year earlier. For the nine months ended September 30, 2021, total revenues were $983.8 million (up 37%) and net income was $135.9 million. Growth was driven by net product revenues, which reached $263.1 million in the quarter (up 56%), with CABOMETYX accounting for $259.8 million. The company attributed the CABOMETYX increase primarily to strong uptake of the combination therapy with OPDIVO following its January 2021 FDA approval for first-line advanced renal cell carcinoma. Operating results also reflected higher spending. Selling, general and administrative expenses rose to $101.6 million in the quarter from $88.2 million, while research and development expenses fell to $163.4 million from $176.8 million. Cash, cash equivalents, restricted cash equivalents and investments totaled $1.8 billion at September 30, 2021, compared with $1.5 billion at December 31, 2020, and operating cash flow for the nine months was $304.4 million. Management expects its resources to fund operations for at least 12 months after the filing date. The principal risk highlighted is patent litigation over CABOMETYX. Abbreviated New Drug Applications from MSN Pharmaceuticals and Teva Pharmaceuticals seek approval of generic versions, and the company has sued both. Bench trials are scheduled for May 2022 (MSN) and June 2023 (Teva). The filing states that approval of either ANDA could significantly decrease U.S. CABOMETYX revenues and materially harm the business, and that it is not possible to determine the likelihood or amount of any potential loss.
- 2022-Q2Aug 5, 2021
Exelixis Quarterly Report for Q2 Ended Jul 2, 2021
Exelixis, Inc. reported strong second-quarter 2021 results in this Form 10-Q, with total revenues of $385.2 million for the three months ended June 30, 2021, compared to $259.5 million a year earlier, and net income of $96.1 million, or $0.30 per diluted share. Net product revenues from CABOMETYX rose to $275.6 million for the quarter, which the filing attributes primarily to strong uptake of the CABOMETYX and OPDIVO combination following FDA approval in January 2021. Collaboration services revenues were $61.3 million, boosted by a cumulative catch-up for Ipsen's share of COSMIC-311 development costs, while license revenues declined to $39.6 million. Operating expenses rose, with research and development expenses of $148.8 million and selling, general and administrative expenses of $98.5 million for the quarter. Cash, cash equivalents, restricted cash equivalents and investments totaled $1.7 billion at June 30, 2021, up from $1.5 billion at December 31, 2020. The filing highlights ongoing patent litigation over generic versions of CABOMETYX. MSN Pharmaceuticals' ANDA litigation has been consolidated with a bench trial scheduled for May 2022, and Teva filed a Paragraph IV ANDA that Exelixis challenged with a complaint filed June 17, 2021. The company states that approval of either generic could significantly decrease U.S. CABOMETYX revenues. Management expects the company to maintain operations for at least 12 months from the filing date and projects that R&D and SG&A expenses will continue to increase for the remainder of 2021. Pipeline activity included the June 2021 sNDA submission for CABOMETYX in differentiated thyroid cancer, which the company stated was accepted with a PDUFA goal date of December 4, 2021. Phase 3 COSMIC-312 met one of its primary endpoints, showing significant PFS improvement versus sorafenib, while the OS endpoint showed a trend that did not reach statistical significance. The company anticipates the OS result will reach final analysis in early 2022.
- 2022-Q1May 6, 2021
Exelixis Quarterly Report for Q1 Ended Apr 2, 2021
Exelixis, Inc. reported net income of $1,601 thousand, or $0.01 per share basic and $0.00 per share diluted, for the three months ended March 31, 2021, compared with net income of $48,612 thousand, or $0.16 per share basic and $0.15 per share diluted, for the first quarter of 2020. Total revenues rose to $270.2 million from $226.9 million, driven by net product revenues of $227.2 million (CABOMETYX $223.6 million, COMETRIQ $3.6 million) and collaboration revenues of $43.0 million. However, research and development expenses increased to $159.3 million from $101.9 million and selling, general and administrative expenses increased to $102.4 million from $62.9 million, resulting in a loss from operations of $4.6 million compared with income from operations of $52.8 million in the prior-year quarter. A $3.6 million income tax benefit contributed to the small net income for the quarter. The company's cash, cash equivalents, restricted cash equivalents and investments totaled $1.6 billion at March 31, 2021, up from $1.5 billion at December 31, 2020, and management anticipates its resources will sustain operations for at least 12 months following the filing date. Net cash provided by operating activities was $39.5 million for the quarter. The filing states that the FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment for advanced RCC in January 2021, and management projects net product revenues for the remainder of 2021 may increase relative to the prior year period. The filing also highlights material risk: MSN Pharmaceuticals and Teva Pharmaceuticals have filed ANDAs seeking approval of generic versions of CABOMETYX tablets. Exelixis has sued MSN, with a bench trial scheduled for May 2022, and states that approval of either generic could significantly decrease U.S. CABOMETYX revenues.
- 2021-Q3Nov 5, 2020
Exelixis Quarterly Report for Q3 Ended Oct 2, 2020
Exelixis, Inc. reported third-quarter 2020 total revenues of $231.1 million, down from $271.7 million a year earlier, driven by lower net product revenues of $168.6 million (versus $191.8 million) and lower license revenues of $33.2 million (versus $69.1 million). Collaboration services revenues rose to $29.3 million from $10.8 million. The company posted a third-quarter net loss of $32.0 million, or $(0.10) per share, compared with net income of $97.5 million in the prior-year quarter, as research and development expenses increased to $176.8 million from $97.3 million and selling, general and administrative expenses rose to $88.2 million from $51.3 million. For the nine months ended September 30, 2020, the company reported net income of $83.4 million and total revenues of $717.5 million. Cash and investments totaled $1.5 billion at September 30, 2020, compared with $1.4 billion at December 31, 2019. The filing highlights the company's dependence on CABOMETYX, whose net product revenues for the quarter were $159.6 million versus $187.4 million a year earlier, and on continued clinical development of cabozantinib. Management cited a sNDA submission for CABOMETYX in combination with Opdivo for advanced renal cell carcinoma, which the FDA accepted with a PDUFA goal date of February 20, 2021. Management also noted a COVID-19 impact described as modest, including a decrease in CABOMETYX prescriptions in the second and third quarters of 2020. The company expects research and development and SG&A expenses to increase in 2020 and expects net product revenues to modestly decrease. A key risk disclosed is litigation with MSN Pharmaceuticals over an ANDA seeking approval of a generic version of CABOMETYX tablets. The company stated that a generic version approved before patent expiration could significantly decrease revenues. A bench trial is scheduled for May 2022, and the filing states it is not possible at this time to determine the likelihood or amount of any unfavorable outcome.
- 2021-Q2Aug 6, 2020
Exelixis Quarterly Report for Q2 Ended Jul 3, 2020
Exelixis, Inc. reported net income of $66.8 million ($0.21 per diluted share) for the second quarter of 2020, compared to $79.0 million ($0.25 per diluted share) in the second quarter of 2019. Total revenues rose to $259.5 million from $240.3 million, driven by higher license revenues ($59.2 million vs. $37.7 million) and collaboration services revenues ($21.5 million vs. $8.9 million), while net product revenues declined to $178.7 million from $193.7 million. CABOMETYX net product revenues were $173.6 million versus $189.0 million a year earlier, which the company partly attributes to COVID-19 effects on patient access to healthcare professionals and ordering patterns. Research and development expenses rose to $114.9 million from $81.9 million, mainly due to higher clinical trial costs for the cabozantinib development program. The balance sheet strengthened over the period. Cash and investments totaled $1.5 billion as of June 30, 2020, and cash and cash equivalents were $527.1 million. Total stockholders' equity increased to $1.83 billion from $1.69 billion at December 31, 2019. The company states it expects its current cash, short-term investments and revenues to fund operations for at least 12 months following the filing date. The filing highlights a material legal risk: MSN Pharmaceuticals filed an ANDA seeking approval to market a generic version of CABOMETYX tablets, and Exelixis has sued MSN in the District of Delaware. The company states that early generic entry could significantly decrease revenues and materially harm the business, and that it is not possible at this time to determine the likelihood of an unfavorable outcome. A bench trial is scheduled for May 2022. Other highlights include the CheckMate-9ER results for cabozantinib plus nivolumab and planned regulatory submissions.
- 2021-Q1May 5, 2020
Exelixis Quarterly Report for Q1 Ended Apr 3, 2020
Exelixis, Inc. reported net income of $48.6 million, or $0.16 per share basic and $0.15 diluted, for the three months ended March 31, 2020, compared with $75.8 million, or $0.25 basic and $0.24 diluted, in the first quarter of 2019. Total revenues were $226.9 million versus $215.5 million a year earlier, driven by net product revenues of $193.9 million (CABOMETYX $189.2 million, COMETRIQ $4.7 million). Research and development expenses rose to $101.9 million from $63.3 million, mainly on clinical trial costs for the cabozantinib program, and SG&A was $62.9 million. Income from operations fell to $52.8 million from $84.6 million. The balance sheet remained strong, with cash and cash equivalents of $357.3 million and short-term and long-term investments totaling about $1.1 billion, for total cash and investments of $1.4 billion at both March 31, 2020 and December 31, 2019. Operating cash flow was $56.1 million, down from $161.6 million, which the company attributed to a $48.0 million decrease in milestone payments received and higher operating expenses. Management states it expects liquidity to sustain operations for at least 12 months following the filing date. The filing highlights COVID-19 effects on clinical trial enrollment and drug discovery, and reports that MSN Pharmaceuticals amended its ANDA to assert Paragraph IV certifications against two additional CABOMETYX patents. Investors should note the reliance on CABOMETYX sales and collaboration partners Ipsen and Takeda for ex-U.S. commercialization, along with the company's expectation that R&D expenses will continue to increase in 2020.
- 2020-Q3Oct 30, 2019
Exelixis Quarterly Report for Q3 Ended Sep 27, 2019
Exelixis, Inc. reported strong third-quarter 2019 results in this Form 10-Q for the period ended September 30, 2019. Total revenues for the quarter were $271.7 million, up from $225.4 million a year earlier, driven by net product revenues of $191.8 million (CABOMETYX $187.4 million) and collaboration revenues of $79.9 million. Net income was $97.5 million, or $0.31 per diluted share, compared with $126.6 million, or $0.41 per diluted share, in the third quarter of 2018. The decline in profit reflected research and development expenses rising to $97.3 million from $44.7 million, and a provision for income taxes of $25.2 million, as the company began recording income tax expense at an estimated rate following the release of its valuation allowance. For the nine months, net income was $252.3 million, and operating cash flow was $368.9 million. Cash and investments totaled $1.2 billion at September 30, 2019. The company stated that it expects its cash resources to sustain operations for at least 12 months from the filing date. Management identified CABOMETYX's commercial performance as the key driver of future cash flow. The filing also highlights legal and commercial developments. In October 2019, MSN Pharmaceuticals filed an ANDA seeking approval of a generic CABOMETYX tablet, and Exelixis sued MSN on October 29, 2019, asserting U.S. Patent No. 8,877,776. The company also entered a build-to-suit lease for approximately 220,000 square feet in Alameda, California, with occupancy anticipated in October 2021.
- 2020-Q2Jul 31, 2019
Exelixis Quarterly Report for Q2 Ended Jun 28, 2019
Exelixis, Inc. reported strong second-quarter 2019 results in this Form 10-Q for the period ended June 30, 2019. Total revenues were $240.3 million for the three months ended June 30, 2019, up from $186.1 million a year earlier, driven by net product revenues of $193.7 million (CABOMETYX net product revenues of $189.0 million). Net income was $79.0 million, or $0.25 per diluted share, compared with $87.5 million, or $0.28 per diluted share, in the prior-year quarter, as research and development expenses rose to $81.9 million from $42.5 million. The company cited the effective tax rate increase to 20.8% from 1.0%, as it released its valuation allowance at year-end 2018. For the six months ended June 30, 2019, net income was $154.8 million, compared with $203.4 million in the prior-year period, which included $45.8 million of Ipsen milestone revenue recognized in the first quarter of 2018. Cash and investments totaled $1,161.0 million at June 30, 2019, compared with $851.6 million at December 31, 2018, and operating activities provided $293.3 million of cash in the first six months. The company stated that its existing resources should support operations for at least 12 months following the filing date. Clinical development activity was extensive, including four phase 3 pivotal studies of cabozantinib (CheckMate 9ER, COSMIC-311, COSMIC-312 and COSMIC-313). In June 2019, Genentech reported that the phase 3 IMspire170 trial of cobimetinib did not meet its primary endpoint. Subsequent to quarter-end, the company entered into an option and license agreement with Aurigene with a $10.0 million upfront payment for three preexisting programs.
- 2020-Q1May 1, 2019
Exelixis Quarterly Report for Q1 Ended Mar 29, 2019
Exelixis, Inc. reported net income of $75.8 million, or $0.25 per share basic and $0.24 per share diluted, for the three months ended March 31, 2019, compared to $115.9 million, or $0.39 basic and $0.37 diluted, for the same period in 2018. Total revenues were $215.5 million versus $213.7 million a year earlier. Net product revenues rose to $179.6 million from $134.3 million, driven by CABOMETYX sales of $175.9 million, while collaboration revenues fell to $35.9 million from $79.4 million, mainly due to lower milestone revenues ($10.0 million versus $66.5 million). Research and development expense increased to $63.3 million from $37.8 million, and selling, general and administrative expense rose to $60.1 million from $54.0 million. Income tax provision increased to $14.9 million from $2.5 million, reflecting the release of substantially all of the valuation allowance against deferred tax assets at December 31, 2018. The balance sheet showed cash, cash equivalents and investments of $1.02 billion at March 31, 2019, up from $851.6 million at December 31, 2018, and operating cash flow of $161.6 million for the quarter. Management anticipates the company's resources will sustain operations for at least 12 months following the filing date, and states that its ability to generate unrestricted cash flow depends on continued commercial success of CABOMETYX, including its newly approved indication in previously treated hepatocellular carcinoma (HCC) in the U.S. in January 2019. The filing also describes a large cabozantinib development program with over 75 ongoing or planned clinical trials, an April 2019 lease amendment for additional Alameda office space, and a Takeda collaboration amendment that increases potential milestone payments to Exelixis by an aggregate $12.0 million, with the Japanese RCC milestone raised from $10.0 million to $16.0 million.
- 2019-Q3Nov 1, 2018
Exelixis Quarterly Report for Q3 Ended Sep 28, 2018
Exelixis, Inc. reported strong third-quarter 2018 results in this Form 10-Q for the period ended September 30, 2018. Total revenues were $225.4 million for the quarter, up from $152.5 million, and $625.2 million for the nine months, up from $332.4 million. Net product revenues, driven by CABOMETYX, were $162.9 million for the quarter. Net income was $126.6 million, or $0.41 per diluted share, for the quarter, and $330.0 million for the nine months. Results for 2018 reflect the adoption of Topic 606 on January 1, 2018, which recorded a net reduction of $258.5 million to opening accumulated deficit and shifted the timing of collaboration revenue recognition. The company ended the quarter with $750.3 million in cash and investments, including $748.7 million available for operations, compared with $457.2 million at December 31, 2017. Operating cash flow for the nine months was $311.1 million. Management states it expects current cash, investments, and revenues to fund operations for at least 12 months after the filing date. Research and development expenses rose to $44.7 million for the quarter from $28.5 million, reflecting clinical trial and personnel costs, while selling, general and administrative expenses rose to $48.1 million from $38.1 million. The filing highlights continued dependence on CABOMETYX's commercial success, with the company noting a 59% increase in CABOMETYX units sold for the quarter. Pending regulatory matters include a PDUFA action date of January 14, 2019 for cabozantinib in previously-treated advanced hepatocellular carcinoma in the U.S., and a positive CHMP opinion in the EU for the same indication. The company also flagged risks including generic competition, pricing scrutiny, and reliance on collaboration partners Ipsen, Takeda, and Genentech.
- 2019-Q2Aug 1, 2018
Exelixis Quarterly Report for Q2 Ended Jun 29, 2018
Exelixis, Inc. reported a strong second quarter of 2018 in its Form 10-Q, with total revenues of $186.1 million, up from $99.0 million in the second quarter of 2017, and net income of $87.5 million, or $0.28 per diluted share, compared with $17.7 million, or $0.06 per share, a year earlier. Net product revenues were $145.8 million, driven by CABOMETYX sales of $141.1 million, while collaboration revenues rose to $40.3 million. The results were affected by the adoption of ASU Topic 606 on January 1, 2018, which the company says reduced second-quarter collaboration revenues by $54.1 million and reduced net income by $53.1 million relative to the prior accounting method. Six-month net income was $203.4 million, including a $258.5 million reduction to the opening accumulated deficit from the Topic 606 transition. Operating expenses increased, with research and development rising to $42.5 million and selling, general and administrative expenses to $51.9 million in the quarter. Cash, cash equivalents and investments totaled $595.9 million at June 30, 2018, compared with $457.2 million at December 31, 2017, and management states that current resources should fund operations for at least 12 months after the filing date. Total stockholders' equity increased to $775.0 million from $285.0 million at year-end 2017. Key pipeline events include a supplemental NDA for CABOMETYX in previously treated advanced hepatocellular carcinoma accepted by the FDA with a PDUFA action date of January 14, 2019, and new collaborations with StemSynergy and Invenra. The company also disclosed that Genentech's IMblaze370 phase 3 trial of cobimetinib in colorectal cancer did not meet its primary endpoint, and that Ipsen's cumulative net sales reached $150.0 million, raising Exelixis' royalty rate to 22% of net sales.
- 2019-Q1May 2, 2018
Exelixis Quarterly Report for Q1 Ended Mar 30, 2018
Exelixis, Inc. reported net income of $115.9 million, or $0.39 per share basic and $0.37 per share diluted, for the three months ended March 31, 2018, compared with $16.7 million, or $0.06 basic and $0.05 diluted, for the same period in 2017. Total revenues rose to $212.3 million from $80.9 million, driven by net product revenues of $134.3 million (up from $68.9 million, with CABOMETYX at $128.9 million) and collaboration revenues of $78.1 million (up from $12.0 million). The results were materially affected by the adoption of ASC Topic 606 on January 1, 2018, which reduced accumulated deficit by $258.5 million and accelerated recognition of certain upfront payments and milestones. Management states that the company recognized $45.8 million related to a $50.0 million Ipsen milestone expected in the second quarter of 2018, and that the company's unrestricted cash generation depends on the commercial success of CABOMETYX in advanced renal cell carcinoma. Cash, cash equivalents and restricted cash stood at $234.3 million at March 31, 2018, and cash and investments totaled $525.6 million, compared with $457.2 million at December 31, 2017. Operating activities provided $71.8 million in cash during the quarter. Total stockholders' equity increased to $669.8 million from $285.0 million, reflecting the net income and the Topic 606 accumulated deficit adjustment. Management believes current resources will fund operations for at least 12 months following the filing date, while stating it expects research and development expenses to increase in 2018. The filing also describes a pending sNDA submitted to the FDA on March 15, 2018 for cabozantinib in previously treated advanced hepatocellular carcinoma, based on the CELESTIAL phase 3 trial, and a May 2, 2018 collaboration with Invenra, Inc. with an upfront payment of $2.0 million and milestone payments of up to $131.5 million for the first indication. Management notes that the company has a history of net losses and that profitability may not be sustained on a quarterly or annual basis.
- 2018-Q3Nov 1, 2017
Exelixis Quarterly Report for Q3 Ended Sep 29, 2017
Exelixis, Inc. reported a substantially improved third quarter and nine months of 2017 in this Form 10-Q. Total revenues were $152.5 million for the three months ended September 30, 2017, compared with $62.2 million a year earlier, and $332.4 million for the nine months, compared with $113.9 million. Net product revenues were $96.4 million for the quarter, driven by CABOMETYX ($90.4 million), while COMETRIQ fell to $6.1 million. The company recorded net income of $81.4 million, or $0.26 per diluted share, for the quarter and $115.7 million for the nine months, compared with net losses in the prior-year periods. Results were boosted by $45.0 million in milestones from Ipsen tied to an EMA validation for a first-line RCC indication. The balance sheet shows cash and investments of $422.3 million at September 30, 2017, down from $479.6 million at December 31, 2016. The company repaid its Deerfield Notes in June 2017 and its Silicon Valley Bank term loan in March 2017, eliminating its debt, and total stockholders' equity rose to $238.7 million from $89.3 million. Operating cash flow was $112.3 million for the nine months, while financing activities used $169.2 million, mainly for debt repayment. Management stated that current cash is expected to fund operations for at least 12 months after the filing date. Key pipeline and business events included an sNDA for cabozantinib in previously untreated advanced RCC, accepted with Priority Review and a PDUFA action date of February 15, 2018, and the CELESTIAL phase 3 trial in advanced HCC meeting its overall survival endpoint, with an sNDA planned for the first quarter of 2018. The company also settled its arbitration with Genentech in June 2017 without payments and amended the COTELLIC collaboration, and it plans to scale back personal promotion of COTELLIC with Zelboraf beginning January 2018.
- 2018-Q2Aug 2, 2017
Exelixis Quarterly Report for Q2 Ended Jun 30, 2017
Exelixis, Inc. reported net income of $17.7 million, or $0.06 per share basic and diluted, for the three months ended June 30, 2017, compared with a net loss of $34.8 million, or $(0.15) per share, in the same period of 2016. Total revenues rose to $99.0 million from $36.3 million, driven by net product revenues of $88.0 million, which reflect CABOMETYX sales of $80.9 million and COMETRIQ sales of $7.1 million in the quarter. For the six months ended June 30, 2017, net income was $34.4 million and total revenues were $179.9 million, compared with a net loss of $94.1 million and revenues of $51.7 million a year earlier. The company's balance sheet shows cash and investments of $380.3 million at June 30, 2017, down from $479.6 million at December 31, 2016. During the quarter Exelixis repaid all outstanding Deerfield Notes for $123.8 million on June 28, 2017, recording a $6.2 million loss on extinguishment, and earlier repaid its $80.0 million Silicon Valley Bank term loan on March 29, 2017. Upfront payments from Takeda ($50.0 million, February 2017) and Ipsen collaboration revenue continued to be recognized over time, and deferred revenue totaled $284.9 million at period end. The company states that its cash will support operations for at least 12 months following the filing date. Management states that its ability to generate meaningful revenue depends on the commercial success of CABOMETYX for advanced renal cell carcinoma. The filing says the company plans to submit a supplemental New Drug Application to the FDA for cabozantinib in previously untreated advanced RCC in the third quarter of 2017, based on CABOSUN results. The company also settled its arbitration with Genentech in June 2017; a July 19, 2017 amendment revised the COTELLIC revenue and cost-sharing arrangement effective July 1, 2017, with no settlement payment. The company also disclosed that it will continue to incur significant development costs and that it has an accumulated deficit of $1.9 billion.
- 2018-Q1-AJul 14, 2017
Exelixis Quarterly Report (Amendment) for Q1 Ended Mar 31, 2017
Exelixis, Inc. filed this Amendment No. 1 on Form 10-Q/A to its Quarterly Report for the quarterly period ended March 31, 2017. The amendment is exhibit-only. Its sole purpose is to re-file Exhibit 10.1, the Collaboration and License Agreement dated January 30, 2017 between Exelixis, Inc. and Takeda Pharmaceutical Company Limited, in response to SEC comments on the company's request for confidential treatment of certain portions of that exhibit. New certifications from the principal executive officer and principal financial officer under Rule 12b-15 are also filed with the amendment. The filing states that it does not reflect events after the original Form 10-Q and makes no revisions to the company's financial statements or other disclosures in that report. It therefore does not add new financial results, guidance, or operating updates. The cover page reports that Exelixis is a large accelerated filer and not a shell company. It lists 292,512,348 shares of common stock outstanding as of April 24, 2017.
- 2018-Q1May 1, 2017
Exelixis Quarterly Report for Q1 Ended Mar 31, 2017
Exelixis, Inc. reported net income of $16.7 million, or $0.06 per share basic and $0.05 per share diluted, for the three months ended March 31, 2017, compared with a net loss of $59.2 million, or $(0.26) per share, in the first quarter of 2016. Total revenues rose to $80.9 million from $15.4 million, driven by net product revenues of $68.9 million, including $62.4 million from CABOMETYX, which launched in late April 2016, and collaboration revenues of $12.0 million. Operating income was $20.2 million, compared with an operating loss of $49.1 million a year earlier. Research and development expenses fell to $23.2 million from $28.9 million, and selling, general and administrative expenses were $34.3 million. The company repaid its $80.0 million Silicon Valley Bank term loan on March 29, 2017. Liquidity remains concentrated in cash and investments, which totaled $475.8 million at March 31, 2017, including $471.6 million available for operations, versus $479.6 million at December 31, 2016. Management stated that current cash and short-term investments should fund operations for at least 12 months following the filing date. The company intends to prepay the Deerfield Notes, carrying $113.9 million of principal and a 15% total interest rate, on or about July 1, 2017, at 105% of principal plus accrued interest, which will require a substantial portion of its cash. Stockholders' equity was $119.8 million at quarter end, and the company reported an accumulated deficit of $2.0 billion. Management cautioned that profitability may not be sustained on a quarterly or annual basis. During the quarter the company entered new collaborations, including a Takeda agreement for cabozantinib in Japan with a $50.0 million upfront payment and up to $95.0 million in development, regulatory and first-sales milestones, plus Bristol-Myers Squibb and Roche clinical trial collaborations. Genentech withdrew its counterclaim in the ongoing JAMS arbitration over COTELLIC, although other significant disputes remain unresolved. The company also disclosed a correction of an immaterial error that overstated interest expense by $2.1 million for the first quarter of 2016.
- 2017-Q3Nov 3, 2016
Exelixis Quarterly Report for Q3 Ended Sep 30, 2016
Exelixis, Inc. reported a third-quarter 2016 net loss of $11.3 million on total revenues of $62.2 million, compared with a net loss of $45.5 million and revenues of $9.9 million in the third quarter of 2015. For the nine months ended September 30, 2016, the company reported total revenues of $113.9 million and a net loss of $105.3 million. Net product revenues from CABOMETYX and COMETRIQ were $42.7 million for the quarter, and the company cited the April 2016 launch of CABOMETYX as the driver of growth. Royalty, license and contract revenues included recognition of part of the $200.0 million upfront payment from Ipsen, a $15.0 million Daiichi Sankyo milestone and royalties on COTELLIC sales. As of September 30, 2016, Exelixis had $379.6 million in cash and investments, of which $293.8 million was available for operations, and an accumulated deficit of $2.0 billion. Total stockholders' equity was $32.0 million, up from a deficit of $140.8 million at December 31, 2015, largely because of conversions of 2019 Notes into common stock. The company states it expects its current cash, short-term investments and product revenues to fund operations for at least 12 months after the filing date. Debt was $190.9 million at quarter end, including an $80.0 million term loan due May 2017 and a Deerfield Notes balance of $109.0 million carrying amount. The filing also discloses a pending arbitration with Genentech over COTELLIC cost and revenue allocations, in which Genentech has filed a counterclaim for damages. The company also disclosed an immaterial error correction that increased prior-period interest expense and reduced reported net loss and stockholders' equity for prior periods, and it stated that the correction would be applied prospectively.
- 2017-Q1-ASep 30, 2016
Exelixis Quarterly Report (Amendment) for Q1 Ended Apr 1, 2016
Exelixis, Inc. filed Amendment No. 1 to its Quarterly Report on Form 10-Q for the quarterly period ended April 1, 2016. The amendment is an exhibit-only filing made in response to SEC comments on a request for confidential treatment of certain portions of Exhibits 10.3 and 10.4. It re-files those two exhibits, which are the Collaboration and License Agreement and the Supply Agreement, both dated February 29, 2016, between Exelixis and Ipsen Pharma SAS. It also includes new certifications from the principal executive officer and principal financial officer under Rule 12b-15. The filing states that it does not reflect events after the original Form 10-Q and makes no revisions to the company's financial statements or other disclosures in that report. The cover page reports 228,739,657 shares of common stock outstanding as of April 28, 2016, and identifies Exelixis as a large accelerated filer. For investors, the main substance is the existence and dating of the Ipsen collaboration and supply arrangements, which are the agreements the company sought to re-file with certain terms kept confidential. This filing does not provide new financial results or operating metrics.
- 2017-Q2Aug 3, 2016
Exelixis Quarterly Report for Q2 Ended Jul 1, 2016
Exelixis, Inc. reported a net loss of $37.0 million for the three months ended June 30, 2016 and $98.4 million for the six months, compared with $43.4 million and $78.5 million in the prior-year periods. Total revenues rose to $36.3 million for the quarter (from $8.0 million) and $51.7 million for the six months (from $17.4 million), driven by the commercial launch of CABOMETYX following FDA approval on April 25, 2016, and by license revenue from the Ipsen collaboration. Net product revenues were $31.6 million for the quarter, of which CABOMETYX contributed $17.6 million and COMETRIQ $14.0 million. Selling, general and administrative expenses rose sharply to $35.8 million in the quarter from $12.8 million, reflecting sales force expansion and launch marketing. Liquidity is a central investor consideration. As of June 30, 2016, the company held $384.0 million in cash and investments, of which $298.2 million was available for operations, $81.6 million was compensating balance on deposit with Silicon Valley Bank, and $4.2 million was long-term restricted. Total debt carried at $396.1 million, including $80.0 million term loan due May 2017 and $107.5 million classified as current. The stockholders' deficit was $186.1 million and the accumulated deficit reached $2.0 billion. Management states current resources should fund operations for at least 12 months after the filing date, but may require earlier capital raising. The filing also discloses a June 3, 2016 arbitration demand against Genentech over COTELLIC cost and revenue allocations, with Genentech counterclaiming for monetary damages, and a positive CHMP opinion on July 22, 2016 for cabozantinib in advanced RCC in the European Union. The $200.0 million upfront payment from Ipsen, received in March 2016, is being recognized ratably, leaving $195.0 million of deferred revenue in total on the balance sheet.
- 2017-Q1May 4, 2016
Exelixis Quarterly Report for Q1 Ended Apr 1, 2016
Exelixis, Inc. reported a net loss of $61.3 million for the three months ended March 31, 2016, compared with $35.2 million in the prior-year period, and total revenues of $15.4 million versus $9.4 million. Total operating expenses rose to $64.6 million from $32.1 million, driven by selling, general and administrative expenses of $34.9 million (up from $9.5 million) as the company expanded its sales force ahead of the CABOMETYX launch, and research and development expenses of $28.9 million (up from $22.3 million). The accumulated deficit reached $2.0 billion and total stockholders' deficit was $156.0 million at March 31, 2016. Cash and investments totaled $407.6 million, of which $323.3 million was available for operations, and the company stated it expects current resources, short-term investments and product revenues to fund operations for at least 12 months from the filing date. The quarter's most significant event was the February 29, 2016 collaboration and license agreement with Ipsen Pharma SAS for cabozantinib outside the United States, Canada and Japan. Ipsen paid a nonrefundable upfront payment of $200.0 million in March 2016, which is being recognized ratably as license revenue, and it is the main reason operating cash flow was $154.9 million for the quarter. Deferred revenue was $14.4 million current and $184.4 million long-term at quarter end. The FDA approved CABOMETYX tablets for previously treated advanced renal cell carcinoma on April 25, 2016, after the quarter ended, and the company shipped product within three days of approval. The filing also discloses a formal notice of dispute issued to Genentech on May 3, 2016 regarding cost and revenue allocations for COTELLIC in the United States, with arbitration intended if the dispute is not resolved within thirty days. Debt totaled $388.7 million at March 31, 2016, including the 2019 Notes, the Deerfield Notes, and an $80.0 million term loan, and the company may be required to make a $27.5 million mandatory prepayment on the Deerfield Notes in January 2017 linked to the Ipsen upfront payment.
- 2016-Q3Nov 10, 2015
Exelixis Quarterly Report for Q3 Ended Oct 2, 2015
Exelixis, Inc. reported a net loss of $47.6 million for the three months ended September 30, 2015 and $126.1 million for the nine months, compared with $62.6 million and $210.6 million in the prior-year periods. Total revenues were $9.9 million for the quarter, including a $3.0 million milestone payment from Merck related to its worldwide license of the PI3K-delta program, and $27.2 million for the nine months. Net product revenues from COMETRIQ were $6.9 million for the quarter and $24.2 million for the nine months. Research and development expense fell to $26.1 million in the quarter from $43.6 million a year earlier, mainly due to lower clinical trial costs, while selling, general and administrative expense rose to $17.8 million from $9.9 million, driven by marketing costs and stock-based compensation. At September 30, 2015, cash, cash equivalents and investments totaled $282.1 million, of which $197.8 million was available for operations. The company completed a public offering in July 2015 of 28,750,000 shares at $5.40 per share, with net proceeds of approximately $145.6 million. Total stockholders' deficit was $74.2 million and the accumulated deficit reached $1.9 billion. Total debt was $377.9 million, and the company states that its current resources should fund operations for at least 12 months following the end of the third quarter of 2015, while noting it may need to raise additional capital significantly earlier than anticipated. The filing centers on cabozantinib, where the phase 3 METEOR trial in advanced renal cell carcinoma met its primary progression-free survival endpoint, the FDA granted Breakthrough Therapy Designation in August 2015, and a rolling New Drug Application was initiated in October 2015. The filing also notes that on November 10, 2015 the FDA approved cobimetinib (COTELLIC) with vemurafenib for BRAF V600 mutation-positive advanced melanoma, a partnered compound for which Exelixis expects a share of U.S. profits and losses under its Genentech collaboration.
- 2016-Q2Aug 11, 2015
Exelixis Quarterly Report for Q2 Ended Jul 3, 2015
Exelixis, Inc. reported a net loss of $43.4 million for the three months ended June 30, 2015, compared with $73.4 million in the prior-year quarter, and a net loss of $78.5 million for the six months ended June 30, 2015 versus $148.0 million a year earlier. Net product revenues for the quarter were $8.0 million, up from $6.6 million, driven by continued ramp-up of COMETRIQ sales. Research and development expenses fell to $24.5 million from $51.0 million, primarily due to lower clinical trial costs following the failure of the COMET-1 and COMET-2 prostate cancer trials and the related 2014 restructuring. The company had an accumulated deficit of $1.8 billion and a total stockholders' deficit of $188.2 million at June 30, 2015. Cash and cash equivalents were $61.9 million, with total cash and investments of $167.0 million, of which $76.6 million was described as available for operations. Liquidity was supported by subsequent events. On July 29, 2015, Exelixis completed an underwritten public offering of 28,750,000 shares at $5.40 per share, with net proceeds of $145.5 million. The company states that its current cash, short-term investments, product revenues and the offering proceeds will fund operations for at least 12 months following the second quarter of 2015. Total outstanding debt was $371.2 million at June 30, 2015, including $287.5 million face amount of 2019 convertible notes and the Deerfield Notes, which were extended to July 1, 2018 and now bear 15% total interest, split between cash and paid-in-kind payments. The key pipeline event was positive top-line results from the phase 3 METEOR trial of cabozantinib in advanced renal cell carcinoma, announced July 20, 2015. The trial met its primary progression-free survival endpoint, with a hazard ratio of 0.58, and the company expects to complete U.S. and EU regulatory filings in early 2016. The FDA extended the action date for Genentech's cobimetinib NDA to November 11, 2015. The company also noted that 6,982,603 performance-based stock options vested on July 20, 2015, which will result in $9.7 million of stock-based compensation expense in the third quarter.
- 2016-Q1Apr 30, 2015
Exelixis Quarterly Report for Q1 Ended Apr 3, 2015
Exelixis, Inc. reported a net loss of $35.2 million for the three months ended March 31, 2015, compared with $74.6 million in the prior-year period, on net product revenues of $9.4 million (up from $4.9 million). The company's revenue comes from sales of COMETRIQ, which included a one-time $2.6 million benefit from changing to the "sell-in" revenue recognition model in January 2015. Research and development expenses fell to $22.3 million from $54.8 million, mainly due to lower clinical trial costs following the failed COMET-1 and COMET-2 prostate cancer trials and the 2014 Restructuring. Accumulated deficit reached $1.8 billion and stockholders' deficit was $146.8 million at quarter end. Liquidity is the central investor concern. Cash, cash equivalents and investments totaled $197.6 million at March 31, 2015, of which $107.2 million was available for operations. The company states it expects to fund operations through the first quarter of 2016, and that this depends heavily on the results of the METEOR phase 3 trial in metastatic renal cell carcinoma, now expected in late Q2 or early Q3 2015. The Deerfield Notes ($104.0 million principal) are expected to be extended to July 1, 2018 on July 1, 2015, and the company states it may need to raise additional capital through equity, debt, or partnering. Other developments include the FDA's April 8, 2015 Fast Track designation for cabozantinib in advanced RCC, a priority review with a PDUFA date of August 11, 2015 for Genentech's cobimetinib NDA, and a non-met primary endpoint in the NCI-CTEP phase 2 ovarian cancer trial versus paclitaxel. Total debt was $368.4 million at March 31, 2015, including the $287.5 million face amount of 2019 convertible notes.
- 2015-Q3Nov 4, 2014
Exelixis Quarterly Report for Q3 Ended Sep 26, 2014
Exelixis, Inc. reported a net loss of $62.6 million for the third quarter of 2014 and $210.6 million for the nine months ended September 30, 2014, with an accumulated deficit of $1.7 billion. Total revenues were $6.3 million for the quarter, all from net product revenues of COMETRIQ, compared with $5.5 million a year earlier. Cash and investments totaled $293.5 million at September 30, 2014, down from $415.9 million at December 31, 2013, and stockholders' equity moved to a deficit of $58.5 million from equity of $66.2 million. The quarter was dominated by the failure of COMET-1, a phase 3 trial of cabozantinib in metastatic castration-resistant prostate cancer, which did not meet its primary overall survival endpoint. Exelixis responded with a 2014 Restructuring, initiated September 2, 2014, that the company expects will reduce its workforce by approximately 65%, or about 150 employees, leaving roughly 80. The company now focuses its resources on phase 3 trials in metastatic renal cell carcinoma and advanced hepatocellular carcinoma. It expects to fund operations through the end of 2015, and it anticipates that it will exercise an option to extend the Deerfield Notes to July 1, 2018, subject to conditions. Total debt was $355.2 million at September 30, 2014, including the 2019 Convertible Notes and the Deerfield Notes, with $97.3 million classified as current. The filing also reports that the EXAM phase 3 trial in MTC did not reach statistical significance on overall survival, and that Genentech's coBRIM phase 3 trial of cobimetinib with vemurafenib met its primary PFS endpoint.
- 2015-Q2Jul 31, 2014
Exelixis Quarterly Report for Q2 Ended Jun 27, 2014
Exelixis, Inc. reported a net loss of $73.4 million for the three months ended June 30, 2014 and $148.0 million for the six months, compared with $62.2 million and $106.9 million in the prior-year periods. Total revenues for the quarter were $6.6 million, all from net product revenues of COMETRIQ, versus $11.9 million a year earlier, when license and contract revenues from Bristol-Myers Squibb made up most of the total. Research and development expenses were $51.0 million in the quarter and $105.8 million for the six months, with the company attributing the increase to clinical trial costs for cabozantinib. Cash and investments totaled $352.0 million at June 30, 2014, down from $415.9 million at December 31, 2013, and the company stated it expects its resources to fund operations for at least 12 months following the end of the second quarter of 2014. Balance sheet pressure is significant. Total stockholders' equity fell to $3.2 million from $66.2 million, and the accumulated deficit reached $1.6 billion. Total debt was $349.0 million, including $173.6 million of the 2019 Convertible Notes, $104.0 million of Deerfield Notes, and $81.1 million under the Silicon Valley Bank facilities, with $95.3 million classified as current. In January 2014 the company sold 10.0 million shares at $8.00 for net proceeds of $75.6 million and amended the Deerfield note agreement, granting an option to extend maturity to July 1, 2018 that expires March 31, 2015. Clinical and partner developments were the main news in the period. Genentech reported positive top-line results from the coBRIM phase 3 study of cobimetinib with vemurafenib in BRAF V600-mutant melanoma on July 11, 2014. The company expects top-line results in 2014 from two phase 3 prostate cancer trials and the EXAM overall survival analysis. Its European partner began commercializing COMETRIQ in the United Kingdom in July 2014, and GlaxoSmithKline gave notice in April 2014 that it would return foretinib.
- 2015-Q1May 1, 2014
Exelixis Quarterly Report for Q1 Ended Mar 28, 2014
Exelixis, Inc. reported a net loss of $74.6 million for the three months ended March 31, 2014, compared with $44.7 million in the prior-year quarter. Total revenues were $4.9 million, consisting entirely of net product revenue from COMETRIQ, down from $9.7 million in the first quarter of 2013, which included $7.8 million of license and contract revenue from Bristol-Myers Squibb. Research and development expenses rose to $54.8 million from $32.7 million, driven predominantly by higher clinical trial costs for the METEOR, COMET-1 and CELESTIAL phase 3 trials, and selling, general and administrative expenses increased to $14.7 million from $10.5 million. Cash and investments totaled $407.7 million at March 31, 2014, and cash used in operating activities was $72.1 million for the quarter. Financing activities provided $65.3 million, mainly from the net proceeds of $75.6 million from a January 2014 offering of 10.0 million common shares at $8.00 per share. The company stated that it expects cash, investments and product revenues to fund operations for at least 12 months following the end of the first quarter of 2014, while noting that future capital requirements will be substantial and additional capital may be needed. Total debt was $343.0 million at March 31, 2014, including the $287.5 million face amount of 4.25% Convertible Senior Subordinated Notes due 2019 and the Deerfield Notes with $104.0 million principal outstanding. In January 2014 the Deerfield note purchase agreement was amended to give Exelixis an option, exercisable through March 31, 2015, to extend maturity to July 1, 2018. Key near-term catalysts cited include top-line results from four of the six ongoing phase 3 pivotal trials expected in 2014, the March 2014 European Commission conditional marketing authorization for COMETRIQ in medullary thyroid cancer, and an IDMC recommendation to continue COMET-1 to its final analysis. The filing also disclosed that GlaxoSmithKline gave notice in April 2014 of its intent to terminate development of foretinib and return it to Exelixis, which would end the collaboration's milestone and royalty eligibility, although GlaxoSmithKline would continue to receive a 3% royalty on cabozantinib-based products. Management reported an accumulated deficit of $1.6 billion, and stockholders' equity of $71.5 million at March 31, 2014.
- 2014-Q3Oct 30, 2013
Exelixis Quarterly Report for Q3 Ended Sep 27, 2013
Exelixis, Inc. reported a net loss of $67.1 million for the three months ended September 30, 2013 and $174.0 million for the nine months, compared with $32.8 million and $95.5 million in the prior-year periods. Total revenues were $5.5 million for the quarter and $27.0 million for the nine months, including net product revenues of $4.8 million and $10.7 million from COMETRIQ, which became commercially available in late January 2013. Revenue fell from $13.3 million and $39.6 million in the prior-year periods, as collaboration revenue declined, and the company states it does not anticipate further collaborative research and development revenues for the remainder of 2013. Operating expenses rose sharply, with research and development expenses of $47.4 million for the quarter and $129.2 million for the nine months, driven mainly by clinical trial costs for COMET-1 and the start-up of phase 3 trials in renal cell cancer and hepatocellular carcinoma. Selling, general and administrative expenses were $37.3 million for the nine months. Interest expense of $33.7 million for the nine months reflects the 2019 convertible notes issued in August 2012. As of September 30, 2013, cash and investments totaled $464.7 million, and the company states this, together with product revenues, should fund operations for at least 12 months following the third quarter of 2013. Stockholders' equity declined to $132.8 million from $296.4 million at year-end 2012, and the accumulated deficit reached $1.43 billion. The company says its future capital needs are substantial and that it may need to raise additional capital earlier than anticipated. Its debt includes $287.5 million in 2019 convertible notes, $114.0 million in Deerfield notes with mandatory prepayments, including a $10.0 million minimum due in January 2014, and $82.9 million owed to Silicon Valley Bank. The filing also notes covenants requiring minimum collateral deposits with Silicon Valley Bank. Key pipeline milestones cited include top-line data from COMET-1 and COMET-2 in prostate cancer and the EXAM overall survival analysis, all expected in 2014.
- 2014-Q2Aug 6, 2013
Exelixis Quarterly Report for Q2 Ended Jun 28, 2013
Exelixis, Inc. reported a net loss of $62.2 million for the three months ended June 30, 2013, and $106.9 million for the six months, versus $36.5 million and $62.6 million in the prior-year periods. Total revenues for the quarter were $11.9 million, including $4.0 million in net product revenues from COMETRIQ, which became commercially available in late January 2013. Research and development expenses rose to $49.1 million for the quarter from $32.6 million, driven mainly by clinical trial costs for the COMET-1 phase 3 pivotal trial and start-up of phase 3 trials in metastatic renal cell and hepatocellular cancer. Interest expense increased to $11.2 million for the quarter from $4.1 million, reflecting the August 2012 issuance of the 4.25% convertible notes due 2019. Liquidity declined over the period. Cash, cash equivalents and investments totaled $524.3 million at June 30, 2013, and stockholders' equity fell to $196.3 million from $296.4 million at December 31, 2012. Net cash used in operating activities was $94.4 million for the six months. Management states that current cash, investments and product revenues should fund operations for at least 12 months following the end of the second quarter of 2013, but notes that future capital requirements will be substantial and additional capital may be needed sooner than anticipated. Total indebtedness through maturity was $466.3 million, and the Silicon Valley Bank loan agreement requires maintaining specified collateral balances. The company stated that it is focusing its resources exclusively on cabozantinib (COMETRIQ), has completed the last of five restructurings since March 2010 affecting 429 employees, and has aggregate restructuring charges of $52.8 million. A former officer has filed a lawsuit seeking unspecified damages, which management intends to defend vigorously and for which it cannot reasonably estimate a loss.
- 2014-Q1May 7, 2013
Exelixis Quarterly Report for Q1 Ended Mar 29, 2013
Exelixis, Inc. reported a net loss of $44.7 million for the three months ended March 31, 2013, compared with a net loss of $26.2 million in the prior-year period. Total revenues were $9.7 million, down from $18.5 million, with the decline primarily attributed to $10.7 million of revenue recognized in 2012 from completion of the technology transfer under the December 2011 Merck license agreement. Net product revenues from COMETRIQ, which became commercially available in late January 2013, were $1.9 million. Interest expense rose to $11.1 million from $4.0 million, reflecting the August 2012 issuance of $287.5 million of 4.25% convertible senior subordinated notes due 2019 and non-cash interest expense of $6.3 million. As of March 31, 2013, the company had $566.8 million in cash and investments, compared with $634.0 million at December 31, 2012. Net cash used in operating activities was $54.4 million for the quarter, and total debt stood at $330.9 million. Management anticipates that current cash, investments and product revenues will enable operations for at least 12 months following the end of the first quarter of 2013, but states that future capital requirements will be substantial and additional capital may be needed. The filing notes that the company must maintain collateral balances under its Silicon Valley Bank loan agreement, and that failure to comply could result in acceleration of the underlying debt. The company is focusing its resources exclusively on cabozantinib (COMETRIQ), which is approved in the United States for progressive, metastatic medullary thyroid cancer and is being evaluated in multiple phase 3 trials, including two in metastatic castration-resistant prostate cancer. The company reported an accumulated deficit of $1.3 billion and stated it is not a party to any material legal proceedings, aside from a December 2012 lawsuit by a former officer that management intends to defend vigorously.
- 2013-Q3Nov 7, 2012
Exelixis Quarterly Report for Q3 Ended Sep 30, 2012
Exelixis, Inc. reported a net loss of $32.8 million for the third quarter of 2012 and a net loss of $95.5 million for the nine months ended September 30, 2012, compared with net income of $77.9 million and $29.4 million in the prior-year periods. Total revenues fell to $13.3 million for the quarter from $128.3 million a year earlier, mainly due to the acceleration of license revenue recognized in 2011 from the terminated Bristol-Myers Squibb XL281 agreement and the Sanofi transfer and termination. Operating expenses were $38.8 million in the quarter, including research and development expenses of $30.7 million, and the company states that its cash and investments were $674.7 million at September 30, 2012, which it expects will fund operations for at least 12 months following the end of the third quarter of 2012. The company is focusing its resources exclusively on cabozantinib. Its New Drug Application for cabozantinib in medullary thyroid cancer was accepted by the FDA with a Priority Review designation and a stated action date of November 29, 2012, and a potential U.S. launch is anticipated in late 2012 or early 2013. Two phase 3 pivotal trials in metastatic castration-resistant prostate cancer, COMET-1 and COMET-2, are ongoing, with top-line results currently expected in 2014. On August 14, 2012, Exelixis issued $287.5 million of 4.25% convertible senior subordinated notes due 2019, and concurrently sold 34.5 million shares at $4.25 per share, generating aggregate net proceeds of $416.1 million. Total stockholders' equity rose to $340.8 million from $90.6 million at December 31, 2011, while total liabilities were $421.8 million. The company also has $497.5 million of total consolidated indebtedness through maturity and a covenant requiring cash and cash equivalents of at least $20.0 million as of December 28, 2012, under its Deerfield note purchase agreement.
- 2013-Q2Aug 2, 2012
Exelixis Quarterly Report for Q2 Ended Jun 29, 2012
Exelixis, Inc. reported a net loss of $36.5 million for the three months ended June 30, 2012 (total revenues of $7.8 million, versus $32.2 million a year earlier) and a net loss of $62.6 million for the six months ended June 30, 2012 (total revenues of $26.3 million). Research and development expenses were $32.6 million for the quarter and $65.7 million for the six months, and the company states that it is focusing its proprietary resources exclusively on cabozantinib. The company said the FDA accepted its New Drug Application for cabozantinib in medullary thyroid cancer and granted Priority Review with a stated action date of November 29, 2012. As of June 30, 2012, Exelixis had $294.8 million in cash and cash equivalents, marketable securities and long-term investments, including about $83.7 million that must be kept on deposit with Silicon Valley Bank under its loan covenants. The company stated this should fund operations for approximately 12 months following the end of the second quarter of 2012, and that it will need to raise additional capital. Total stockholders' equity was $99.0 million, and the accumulated deficit reached $1.2 billion. The filing also flags key obligations and risks: $182.7 million of debt outstanding including the Deerfield secured convertible notes, a minimum cash covenant of $20.0 million under the Deerfield note purchase agreement as of December 28, 2012, and the company's stated reliance on partner payments, milestones and royalties for near-term revenue. Restructurings since 2010 have reduced headcount by 422 employees.
- 2013-Q1May 3, 2012
Exelixis Quarterly Report for Q1 Ended Mar 30, 2012
Exelixis, Inc. reported a net loss of $26.2 million ($0.18 per share) for the three months ended March 31, 2012, compared with a net loss of $27.5 million in the prior-year period. Total revenues fell to $18.5 million from $35.9 million, reflecting the transfer of XL147 and XL765 development to Sanofi, the termination of the Sanofi PI3K discovery collaboration and the BMS XL281 agreement, partially offset by $10.7 million recognized under the Merck PI3K-d license. Research and development expenses decreased to $33.1 million from $45.7 million, and general and administrative expenses decreased to $7.9 million from $9.2 million. The company stated it is focusing its proprietary resources exclusively on cabozantinib (XL184). As of March 31, 2012, cash and cash equivalents, marketable securities and long-term investments totaled $332.1 million, including approximately $84.5 million pledged as collateral to Silicon Valley Bank. The company raised approximately $65 million in net proceeds from a February 2012 public offering of 12.7 million shares. Management anticipates current resources will fund operations for at least 12 months following the filing date, but states it will need to raise additional capital, and it identifies a $20.0 million minimum cash covenant under the Deerfield note purchase agreement as of December 28, 2012. Development milestones described in the filing include the planned rolling NDA submission for cabozantinib in medullary thyroid cancer, expected to be completed in the second quarter of 2012, and the planned start of the COMET-1 phase 3 trial in the second quarter of 2012. The company also reported on May 3, 2012 an initial program of twelve proposed clinical trials approved under its CRADA with the NCI-CTEP. Accumulated deficit reached $1.13 billion at March 31, 2012.
- 2012-Q3Oct 27, 2011
Exelixis Quarterly Report for Q3 Ended Sep 30, 2011
Exelixis, Inc. reported a sharp swing to net income for the third quarter and first nine months of 2011, driven primarily by the acceleration of deferred revenue following Bristol-Myers Squibb's termination of the 2008 Agreement. Total revenues were $128.3 million for the three months ended September 30, 2011, compared with $54.5 million a year earlier, and net income was $77.9 million, or $0.59 per diluted share, versus a net loss of $8.6 million in the prior-year quarter. License revenue for the quarter was $122.7 million, including $109.9 million recognized from the accelerated deferred revenue balance. For the nine months, net income was $29.4 million compared with a net loss of $74.5 million in 2010. The company stated it has an accumulated deficit of $1,152.7 million and expects further net losses and negative operating cash flow in the foreseeable future. Cash flows and liquidity remain the central investor concern. Net cash used in operating activities was $130.1 million for the nine months ended September 30, 2011, largely reflecting a $175.2 million reduction in deferred revenue. As of September 30, 2011, the company held $313.1 million in cash and cash equivalents, marketable securities and long-term investments, including about $93.6 million that must be kept on deposit with Silicon Valley Bank. Management states that current resources and expected collaborator funding should sustain operations for at least 12 months from the filing date, but it also warns that substantial future capital will be needed, that the Deerfield convertible notes and Silicon Valley Bank loan carry repayment and covenant requirements, and that additional financing may be dilutive. Strategically, the company is concentrating all proprietary development on cabozantinib (XL184). The filing reports that the Phase 3 EXAM trial in medullary thyroid cancer met its primary endpoint, with median progression-free survival of 11.2 months versus 4.0 months on placebo, and that the company is seeking FDA permission for a rolling NDA submission. Restructuring plans reduced headcount by 402 employees across 2010 and 2011, and the company announced that it would repay the GlaxoSmithKline loan through issuance of 5,537,906 shares of common stock.
- 2012-Q2Aug 4, 2011
Exelixis Quarterly Report for Q2 Ended Jul 1, 2011
Exelixis, Inc. reported a net loss of $20.975 million, or $(0.16) per share, for the three months ended June 30, 2011, compared with a net loss of $22.614 million in the prior-year quarter. For the six months ended June 30, 2011, the net loss was $48.464 million, or $(0.40) per share, versus $65.862 million a year earlier. Total revenues were $32.162 million for the quarter, down from $47.596 million, and $68.056 million for the six months, down from $89.795 million. The filing attributes the revenue decline mainly to reduced collaboration reimbursement revenue after Bristol-Myers Squibb terminated the cabozantinib collaboration in 2010, along with lower sanofi-aventis funding for XL147 and XL765. The company is focusing exclusively on cabozantinib (XL184). Cabozantinib is in a phase 3 registration trial (EXAM) in medullary thyroid cancer, with top-line results expected around the end of the third quarter of 2011 and a rolling NDA submission planned to begin in the fourth quarter of 2011. Bristol-Myers Squibb notified Exelixis on July 8, 2011 that it is terminating the collaboration as to XL281 effective October 8, 2011. As a result, the company expects to recognize approximately $109.9 million and $10.4 million of deferred up-front license revenue in the third and fourth quarters of 2011, respectively. Management expects net income for 2011 because of this acceleration, but anticipates negative operating cash flow for the foreseeable future. Liquidity is a central concern. At June 30, 2011, the company had $353.6 million in cash, marketable securities and long-term investments, including about $95.0 million on deposit with Silicon Valley Bank under loan covenants. The filing states the company expects these resources to fund operations for at least 12 months after the filing date. Stockholders' deficit was $(81.8) million, accumulated deficit was $1,230.5 million, and the company has significant debt, including the Deerfield notes, a Silicon Valley Bank term loan, and a GlaxoSmithKline loan with a final installment of $36.5 million due October 27, 2011.
- 2012-Q1May 3, 2011
Exelixis Quarterly Report for Q1 Ended Apr 1, 2011
Exelixis, Inc. reported a net loss of $27.5 million for the three months ended March 31, 2011, compared with a net loss of $43.2 million in the prior-year period. Total revenues were $35.9 million, versus $42.2 million a year earlier, and the company attributes the decline mainly to a one-time $7.0 million Genentech milestone in 2010 and lower license revenue from the amended 2007 Bristol-Myers Squibb collaboration. Research and development expense fell to $45.7 million from $64.8 million, reflecting restructuring-driven headcount reductions, and the restructuring charge was $4.8 million. The company's cash position strengthened substantially during the quarter. Cash and cash equivalents rose to $202.1 million from $97.4 million at December 31, 2010, following a public offering of 17.3 million shares that netted $179.3 million. Total cash, cash equivalents, marketable securities and long-term investments were $391.7 million at March 31, 2011, of which approximately $94.6 million is on deposit with Silicon Valley Bank under loan covenants. Stockholders' deficit narrowed to $68.7 million from $228.3 million. Management expects the cash and funding from collaborators to support operations for at least 12 months after the filing date, but it also states that significant future capital needs remain and that negative operating cash flow is expected to continue. The company is focused exclusively on cabozantinib (XL184). The filing states that top-line results from the ongoing phase 3 trial in medullary thyroid cancer are expected in the middle of 2011, with a possible U.S. new drug application by the end of 2011. Debt obligations include a $36.2 million GlaxoSmithKline loan due October 27, 2011, and a Deerfield note purchase agreement with covenants tied to minimum cash levels.